Amgen and AWS join forces to leverage generative AI for drug discovery and increased manufacturing efficiency.
New facility in Columbus, Ohio, to integrate AI, sensors, and machine vision for improved packaging lines and predictive maintenance.
Collaboration explores generative AI and machine learning solutions across research, clinical trials, and operations.
Leading biotech firm utilizes AWS artificial intelligence to enhance manufacturing efficiency, delivering medicines faster globally.
Amazon Web Services (AWS) announced at AWS re:Invent that Amgen is expanding its collaboration with AWS to develop generative AI solutions. The goal is to accelerate the discovery, development, and manufacturing of medicines for patients with serious illnesses.
Amgen plans to leverage AWS's reliable global infrastructure to operate its digital data and analytics platform. This platform will enhance operational efficiency and sustainability in its new state-of-the-art drug assembly and packaging facility in Columbus, Ohio.
The facility will feature cutting-edge digital and robotic technologies, including a connected digital platform powered by Amazon SageMaker. This platform will collect and analyze manufacturing data points daily to reduce manual intervention and improve the ergonomic safety of manual activities in the packaging lines.
Additionally, the platform will gather real-time performance metrics integrated with ML models to predict and prevent equipment failures.
In addition, the companies are experimenting with generative AI and ML technology for research and development, including clinical trials. They are exploring solutions for operational and business areas using Amazon Bedrock and Amazon SageMaker JumpStart.
